FDA: PH should continue using AstraZeneca's COVID-19 vaccine | Inquirer News

FDA: PH should continue using AstraZeneca’s COVID-19 vaccine

By: - Reporter / @KAguilarINQ
/ 02:26 PM April 15, 2021

MANILA, Philippines — The Food and Drug Administration (FDA) recommended to the Department of Health (DOH) that the Philippines continues using AstraZeneca’s COVID-19 vaccine in its vaccination program.

In an online Palace briefing, FDA Director-General Eric Domingo said that the World Health Organization, the country’s vaccine experts panel, and the adverse events committee maintained that the vaccine’s benefit outweighs the risks.

“So sumulat ako kanina kay [DOH] Secretary [Francisco] Duque para sabihin sa kanya, i-reiterate the benefit outweighs the risk and that we should continue using the vaccine para sa ating vaccination program,” Domingo said.

Article continues after this advertisement

“Tamang tama naman, padating pa lang yung next vaccine natin, siguro mga two to three weeks, so yung mga nabigyan dati, matutuloy naman yung kanilang second dose,” he added.

FEATURED STORIES

The DOH earlier suspended the use of the AstraZeneca vaccine on individuals aged 60 and below over concerns about rare cases of blood clots detected in persons vaccinated with the jab in other countries.

Domingo earlier said it will release new guidelines on the use of AstraZeneca’s COVID-19 vaccine.

JE
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca, FDA

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.